Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

West Melbourne, Australia Clinical Trials

A listing of West Melbourne, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (113) clinical trials

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Up to a total of 18-24 patients will be enrolled into this study - 6 patients in each dose cohort. The planned sequence of cohort enrollment is 100 mg QD - 200 mg QD - 100 mg BID. Furthermore, an additional cohort of 200 mg BID may also be enrolled, ...

Phase

2.01 miles

Learn More »

STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units

The trial will include patients with acute spontaneous ICH, who are 18 years of age and are eligible for treatment within 2 hours of stroke onset. A sample size of 62 patients is calculated to give 80% power to detect a large effect size assuming mean relative ICH haematoma growth ...

Phase

2.01 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of CRN00808 for the Treatment of Acromegaly

A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 (an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.

Phase

2.01 miles

Learn More »

A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

The primary purpose of this open-label, Phase 2 proof of concept study is to evaluate the efficacy of 12 months of oral ACH-0144471 in participants with C3G or IC-MPGN based on renal biopsy results and the number and percentage of participants with an improvement relative to baseline in clinical manifestation(s) ...

Phase

2.01 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of CRN00808 for the Treatment of Acromegaly

An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of CRN00808 (an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens.

Phase

2.01 miles

Learn More »

Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV

This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074 in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1 reservoir

Phase

2.01 miles

Learn More »

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.

Phase

2.01 miles

Learn More »

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

The primary purpose of this trial is to evaluate the efficacy and tolerability of durvalumab and tremelimumab with platinum-pemetrexed in patients with metastatic NSCLC (T790+ve or T790M-ve) following progression on EGFR Tyrosine Kinase Inhibitors.. Study population: Individuals may be eligible to enrol in this trial if aged 18 or over ...

Phase

2.01 miles

Learn More »

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this ...

Phase

2.08 miles

Learn More »

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced ...

Phase

2.08 miles

Learn More »